医药政策法规
- (2021-11-15)
- (2021-11-12)
- (2021-11-12)
- (2021-11-12)
- (2021-11-12)
- (2021-11-12)
- (2021-11-12)
- (2021-11-12)
- (2021-11-11)
- (2021-11-11)
- (2021-11-11)
- (2021-11-11)
- (2021-11-11)
- (2021-11-11)
- (2021-11-10)
- (2021-11-10)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
新冠疫情:2.5亿!默沙东/Ridgeback抗病毒药物Lagevrio(molnupiravir)获批:首个COVID
(2021-11-09)- (2021-11-09)
- (2021-11-09)
- (2021-11-09)
- (2021-11-05)
- (2021-11-05)
- (2021-11-05)
- (2021-11-04)
- (2021-11-04)
- (2021-11-04)
- (2021-11-04)
- (2021-11-04)
- (2021-11-04)
- (2021-11-03)
- (2021-11-03)
- (2021-11-03)
- (2021-11-03)
- (2021-11-03)
- (2021-11-01)
- (2021-11-01)
- (2021-11-01)
- (2021-11-01)
- (2021-10-29)
- (2021-10-29)
- (2021-10-29)
- (2021-10-29)
- (2021-10-29)
Molecular Therapy Nucleic Acids:LRRC4介导造成环状RNA CD44克制GBM细胞增殖
(2021-10-29)- (2021-10-29)
- (2021-10-29)
- (2021-10-29)
- (2021-10-29)